2230282-02-5
Chemical Structure
Lorpucitinib
Synonym(s): JNJ-64251330
- CAS No.: 2230282-02-5
- Formula:C22H28N6O2
- Molecular Weight:408.50
IUPAC Name: 2-(1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-N-(2-hydroxy-2-methylpropyl)acetamide
InChIKey: NJKMSBSVJSQUBU-SHTZXODSSA-N
SMILES: O=C(NCC(C)(O)C)CC1=NC2=CN=C(NC=C3)C3=C2N1[C@H]4CC[C@H](CC#N)CC4
Biological Activity: Lorpucitinib (JNJ-64251330) is an orally active pan-JAK inhibitor with good enteric selectivity and safety. Lorpucitinib can inhibit the JAK/STAT pathway and reduce the levels of inflammatory biomarkers in serum. Lorpucitinib can be used in the research of familial adenomatous polyposis and gastrointestinal inflammatory diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lorpucitinib | 99.95% | Lorpucitinib (JNJ-64251330) is an orally active pan-JAK inhibitor with good enteric selectivity and safety. Lorpucitinib can inhibit the JAK/STAT pathway and reduce the levels of inflammatory biomarkers in serum. Lorpucitinib can be used in the research of familial adenomatous polyposis and gastrointestinal inflammatory diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lorpucitinib (Standard) | ≥98% | Lorpucitinib (Standard) is the analytical standard of Lorpucitinib (HY-109182). This product is intended for research and analytical applications. Lorpucitinib (JNJ-64251330) is an orally active pan-JAK inhibitor. Lorpucitinib inhibits all four human JAKs, with greatest potency toward JAK1/JAK3 and JAK1/TYK2 heterodimers, and reduces STAT-3 phosphorylation downstream of JAK signaling. Lorpucitinib can be used for the research of gastrointestinal inflammatory diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hüneburg R, et al. Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study. 2023.
- [2]. Ma X, et al. A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants. Clinical Pharmacology & Therapeutics, 2024, 115(5): 1075-1084.
